- Home
- BMRA vs RNAZ Comparison
BMRA vs RNAZ Comparison
Compare BMRA & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- RNAZ
- Stock Information
- Founded
- BMRA 1971
- RNAZ 2016
- Country
- BMRA United States
- RNAZ United States
- Employees
- BMRA N/A
- RNAZ N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- RNAZ Health Care
- Exchange
- BMRA Nasdaq
- RNAZ Nasdaq
- Market Cap
- BMRA 7.4M
- RNAZ 8.3M
- IPO Year
- BMRA N/A
- RNAZ 2021
- Fundamental
- Price
- BMRA $0.33
- RNAZ $0.34
- Analyst Decision
- BMRA
- RNAZ Strong Buy
- Analyst Count
- BMRA 0
- RNAZ 1
- Target Price
- BMRA N/A
- RNAZ $3.00
- AVG Volume (30 Days)
- BMRA 337.1K
- RNAZ 602.3K
- Earning Date
- BMRA 10-15-2024
- RNAZ 11-26-2024
- Dividend Yield
- BMRA N/A
- RNAZ N/A
- EPS Growth
- BMRA N/A
- RNAZ N/A
- EPS
- BMRA N/A
- RNAZ N/A
- Revenue
- BMRA $5,509,000.00
- RNAZ N/A
- Revenue This Year
- BMRA N/A
- RNAZ N/A
- Revenue Next Year
- BMRA N/A
- RNAZ $100.00
- P/E Ratio
- BMRA N/A
- RNAZ N/A
- Revenue Growth
- BMRA 1.74
- RNAZ N/A
- 52 Week Low
- BMRA $0.24
- RNAZ $0.22
- 52 Week High
- BMRA $2.13
- RNAZ $18.68
- Technical
- Relative Strength Index (RSI)
- BMRA 45.05
- RNAZ 32.40
- Support Level
- BMRA $0.34
- RNAZ $0.31
- Resistance Level
- BMRA $0.44
- RNAZ $0.49
- Average True Range (ATR)
- BMRA 0.04
- RNAZ 0.05
- MACD
- BMRA -0.00
- RNAZ -0.02
- Stochastic Oscillator
- BMRA 23.21
- RNAZ 9.64
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.